Skip to main content

The Relationship Between Pre-Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer

In brief

Model predicts 54% response with higher-dose ipilimumab before bladder cancer surgery

In 52 patients with advanced urothelial cancer, a model linked higher ipilimumab exposure and lower nivolumab clearance to response at surgery. It predicted response in 54% with 3 mg/kg ipilimumab versus 29% with 1 mg/kg; 12 of 13 patients with the lowest clearance of both drugs responded. The small study needs confirmation before guiding treatment.

Journal
Clinical and translational science (Q1)
Published
1 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Sybrand W J Zielhuis, Karen A M de Jong, Hinke Huisman-Siebinga, Lisa T van der Heijden, Bart A W Jacobs, Jos H Beijnen, et al.
PMID
43031519
DOI
10.1111/cts.70777

Why clinicians should know about it

  • Picked for Urology (top studies of the week, 15 November 2026): Perioperative immunotherapy exposure and response in urothelial cancer

Abstract

Patients with locoregionally advanced urothelial cancer (UC) received three pre-operative cycles of ipilimumab and nivolumab in the NABUCCO trial, across three cohorts with different dosing combinations. This study aimed to define the pharmacokinetics (PK) of both drugs in this population and to assess the relationship between the PK and treatment response. Ipilimumab and nivolumab serum concentrations were measured in 139 samples of 52 patients. A population PK model was developed for both drugs using nonlinear mixed-effects modeling. This model was used to examine baseline clearance (CL0)- and exposure-response relationships, with pathological response at surgery as efficacy parameter. A logistic regression model was constructed to quantify these relationships. The developed population PK model adequately described ipilimumab and nivolumab observations. Individual CL0 estimates of both drugs were correlated (correlation coefficient = 0.57). Among patients in the lowest quartile of CL0 of both drugs, twelve out of thirteen patients were responders. In the logistic regression model, a relatively low nivolumab CL0 and high ipilimumab exposure were successfully related to treatment response. The model predicted probability of response was higher for high-dose ipilimumab (3 mg/kg) compared to low-dose ipilimumab (1 mg/kg) (54% vs. 29%, respectively), and was in line with NABUCCO trial outcomes. These results support the hypothesis that for ipilimumab, an exposure-response relationship exists, while this is not the case for nivolumab. Further confirmation of these relationships is warranted, given the limited number of patients included in the analysis.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.